The coexistence of atrial fibrillation (AF) and heart failure (HF) represents one of the most frequent and dangerous combinations in modern cardiology, exponentially multiplying patient morbidity and mortality. Their relationship is bidirectional and pathophysiologically intertwined: AF exacerbates HF through rapid and irregular ventricular rates that reduce diastolic filling time and cardiac output, frequently leading to tachycardia-induced cardiomyopathy. Conversely, HF promotes structural and electrical atrial remodeling through dilation and fibrosis, thereby facilitating the maintenance of the arrhythmia.
While rate control strategies constitute common clinical practice, they often fail to adequately address the associated hemodynamic burden. In contrast, rhythm control via catheter ablation directly intervenes in this vicious cycle, restoring atrial contraction, stabilizing diastolic filling, and offering the potential to reverse detrimental myocardial alterations.
Clinical Documentation and Survival Benefit
The superiority of ablation over conventional pharmacological therapy in HF is documented by large randomized clinical trials:
- CASTLE-AF Trial: In patients with symptomatic AF and reduced ejection fraction (LVEF ≤35%), ablation achieved an impressive 38% relative risk reduction in the composite primary endpoint of all-cause mortality and hospitalization for HF. Concurrently, it led to an absolute improvement in left ventricular ejection fraction of approximately 8% [1].
- CASTLE-HTx Trial: The value of this intervention extends even to patients with end-stage heart failure who are candidates for transplantation. Ablation dramatically reduced the rate of death, left ventricular assist device (LVAD) implantation, or urgent transplantation to 8.2% compared to 29.9% in the medical therapy group [2].
- Subgroup Data (CABANA) and Meta-analyses: The HF subgroup in the CABANA trial demonstrated a 36% risk reduction for the composite endpoint of death, stroke, or cardiac arrest [3]. Furthermore, recent meta-analyses confirm that ablation overall improves LVEF and reduces HF hospitalizations [4].
- RAFT-AF Trial: Despite its premature termination, it recorded a significant superiority of ablation in improving ejection fraction (+10.1% versus +3.8% in the rate control group), demonstrating a positive impact on myocardial function [5].
The Methodological Pitfall and the Real Value of the RAFT-AF Trial
The RAFT-AF trial, which compared ablation to rate control therapy in patients with HF, elevated NT-proBNP, and either reduced or preserved ejection fraction (HFrEF and HFpEF), is of particular scientific interest. The study found that ablation numerically reduced the primary endpoint of death and HF admission (23.4% versus 32.5%), but was stopped early due to "futility" regarding the proof of statistically significant superiority.
However, a close reading of the data overturns the superficial impression of a "negative" trial:
- On the Verge of Significance: The result was marginal, with a p-value of 0.066, indicating a strong trend toward benefit.
- Kaplan-Meier Curve Behavior: Looking closely at the survival curves, it is evident that up to the two-year mark, the two groups overlap perfectly. After two years, however, the curves begin to diverge clearly in favor of ablation.
- The Futility Index Error: The statistical committee evaluated the futility index at two years (before the curves had time to separate) and found it to be 0.81 (whereas a study must be below 0.80 to continue). This theoretically implied a mere 19% probability that ablation would be vindicated. The premature termination resulted in the final enrollment of 411 patients instead of the ~600 originally planned, depriving the study of statistical power at the exact moment the ablation benefit was beginning to manifest.
This carries a profound clinical message: restoring sinus rhythm, unlike simple rate control, requires time to translate into a reduction of hard clinical events. The real benefit becomes established after the second year.
Furthermore, regarding the study’s secondary clinical endpoints, ablation achieved clear improvements in ejection fraction, NT-proBNP, exercise capacity, and quality of life. This improvement was significantly greater in two specific patient subgroups:
- In those with an impaired ejection fraction below 45% (HFrEF).
- In those presenting with a high burden of persistent atrial fibrillation.
Patient Selection and Timing (The "Earlier is Better" Hypothesis)
The maximum benefit of ablation is achieved when it is implemented early, ideally within 12 months of the initial AF diagnosis, as also supported by the EAST-AFNET 4 trial [6]. Early intervention prevents the establishment of irreversible myocardial fibrosis.
Patients with a lesser degree of structural atrial remodeling and a pronounced element of tachycardiomyopathy exhibit the highest probability of full functional recovery. Conversely, extensive fibrosis or extreme left atrial dilation (diameter >55 mm) serve as deterrents (red flags), limiting the potential for reverse ventricular remodeling.
Clinical Evaluation and Perioperative Optimization
Linking the aforementioned data to daily clinical practice, the final decision necessitates a dual clinical approach:
- Etiological Correlation (Cause or Effect): The clinician must evaluate whether atrial fibrillation is the primary mechanism that triggered or acutely exacerbated heart failure (pure or contributing tachycardiomyopathy). In cases where the arrhythmia is the main driver of hemodynamic compromise, ablation is recommended promptly to eliminate this compounding factor.
- Pharmacological Stabilization (GDMT): The decision for ablation should not be made under conditions of acute hemodynamic derangement or uncontrolled congestive state. It is imperative that the patient has been previously stabilized to the maximum extent possible with optimal Guideline-Directed Medical Therapy (GDMT). This perioperative optimization reduces atrial filling pressures and myocardial stress, which constitutes a fundamental prerequisite for avoiding early arrhythmia recurrence during the vulnerable healing period (blanking period).
Conclusion
The answer to whether atrial fibrillation ablation is indicated in heart failure is a categorical YES. This is not merely a matter of symptomatic relief, but a disease-modifying therapy that improves prognosis, reduces hospitalizations, enhances quality of life, and prolongs survival. Heart failure is precisely the clinical substrate where rhythm control via ablation is more necessary than ever, offering the maximum possible hemodynamic and clinical benefit to the patient.
References
- Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bänsch D; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018 Feb 1;378(5):417-427. doi: 10.1056/NEJMoa1707855. PMID: 29385358.
- Sohns C, Fox H, Marrouche NF, Crijns HJGM, Costard-Jaeckle A, Bergau L, Hindricks G, Dagres N, Sossalla S, Schramm R, Fink T, El Hamriti M, Moersdorf M, Sciacca V, Konietschke F, Rudolph V, Gummert J, Tijssen JGP, Sommer P; CASTLE HTx Investigators. Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. N Engl J Med. 2023 Oct 12;389(15):1380-1389. doi: 10.1056/NEJMoa2306037. Epub 2023 Aug 27. PMID: 37634135.
- Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, Poole JE, Bahnson TD, Lee KL, Mark DB; CABANA Investigators. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. Circulation. 2021 Apr 6;143(14):1377-1390. doi: 10.1161/CIRCULATIONAHA.120.050991. Epub 2021 Feb 8. PMID: 33554614; PMCID: PMC8030730.
- Demarchi A, Casula M, Annoni G, Foti M, Rordorf R. Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure: Focus on the Latest Clinical Evidence. J Clin Med. 2024 Aug 29;13(17):5138. doi: 10.3390/jcm13175138. PMID: 39274351; PMCID: PMC11395793.
- Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A, Wilton SB, Verma A, Healey JS, Sterns L, Bennett M, Roux JF, Rivard L, Leong-Sit P, Jensen-Urstad M, Jolly U, Philippon F, Sapp JL, Tang ASL. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation. 2022 Jun 7;145(23):1693-1704. doi: 10.1161/CIRCULATIONAHA.121.057095. Epub 2022 Mar 22. PMID: 35313733.
- Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbüchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns HJGM, Breithardt G; EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29. PMID: 32865375.
References
- Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bänsch D; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018 Feb 1;378(5):417-427. doi: 10.1056/NEJMoa1707855. PMID: 29385358.
- Sohns C, Fox H, Marrouche NF, Crijns HJGM, Costard-Jaeckle A, Bergau L, Hindricks G, Dagres N, Sossalla S, Schramm R, Fink T, El Hamriti M, Moersdorf M, Sciacca V, Konietschke F, Rudolph V, Gummert J, Tijssen JGP, Sommer P; CASTLE HTx Investigators. Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. N Engl J Med. 2023 Oct 12;389(15):1380-1389. doi: 10.1056/NEJMoa2306037. Epub 2023 Aug 27. PMID: 37634135.
- Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, Poole JE, Bahnson TD, Lee KL, Mark DB; CABANA Investigators. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. Circulation. 2021 Apr 6;143(14):1377-1390. doi: 10.1161/CIRCULATIONAHA.120.050991. Epub 2021 Feb 8. PMID: 33554614; PMCID: PMC8030730.
- Demarchi A, Casula M, Annoni G, Foti M, Rordorf R. Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure: Focus on the Latest Clinical Evidence. J Clin Med. 2024 Aug 29;13(17):5138. doi: 10.3390/jcm13175138. PMID: 39274351; PMCID: PMC11395793.
- Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A, Wilton SB, Verma A, Healey JS, Sterns L, Bennett M, Roux JF, Rivard L, Leong-Sit P, Jensen-Urstad M, Jolly U, Philippon F, Sapp JL, Tang ASL. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation. 2022 Jun 7;145(23):1693-1704. doi: 10.1161/CIRCULATIONAHA.121.057095. Epub 2022 Mar 22. PMID: 35313733.
- Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbüchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns HJGM, Breithardt G; EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29. PMID: 32865375.